Skip to main content
SpringerLink
Log in

Bone-Specific Drug Delivery Systems

Approaches via Chemical Modification of Bone-Seeking Agents

  • Leading Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Despite several decades of progress, bone-specific delivery is still limited by the unique anatomical features of bone, which mainly consists of inorganic hydroxyapatite. A practical approach to this problem is to produce targeted drugs that have a high affinity for hydroxyapatite. Bisphosphonates are a class of synthetic compounds structurally related to pyrophosphate. Bisphosphonates rapidly localise on the bone surface after being administered either intravenously or orally, since the P-C-P portion of the bisphosphonate structure has high affinity for hydroxyapatite. Therefore, bisphosphonate modification might be a promising method for targeting drugs selectively to the bone.

Bisphosphonate-conjugated drugs are hydrophilic and highly water-soluble due to the acidic nature of the bisphosphonate moiety at physiological pH, and therefore they hardly permeate through the biological membrane of soft tissues. These physicochemical changes also reduce the intrinsic susceptibility of the drug to metabolism, promoting urinary or biliary excretion as unchanged drug. All these physicochemical and pharmacokinetic alterations contribute to the exceptional skeletal disposition of bisphosphonate-conjugated drugs.

Bisphosphonate conjugation is based on chemical modification of the targeting molecule, and therapeutically optimised bisphosphonate derivatives have to be custom-developed on a case-by-case basis. The bisphosphonate moiety is usually coupled with the targeting drug through a specific linkage. The high affinity of bisphosphonate conjugates for the bone is not simply dependent on the bisphosphonate moiety but on the resultant molecule as a whole, including the linker and the linked drug. Lipophilicity (represented as log P) appears to be an appropriate index for predicting the osteotropic properties of bisphosphonate derivatives.

Several strategies using bisphosphonate-conjugated drugs have been investigated at a laboratory level with the aim of obtaining therapeutically optimised treatments for conditions such as osteoporosis, osteoarthritis and bone cancer. In each case, the intention is to achieve prolonged local exposure to high concentrations of the targeting drug, thereby improving therapeutic index by enhancing pharmacological efficacy and minimising systemic adverse effects.

Although most examples of bone-specific drug delivery via bone-seeking agents still remain in preclinical studies, several phosphonate-coupled radiopharmaceuticals, such as samarium-153 complexed to tetraphosphonate, are expected to be an effective pain palliation therapies for metastatic bone cancer and are currently being developed in clinical trials. Furthermore, recent reports on bisphosphonate-modified proteins have illustrated the feasibility of bone-specific delivery of biologically active protein drugs, such as cytokines and growth factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Abbott III TA, Lawrence BJ, Wallach S. Osteoporosis: the need for comprehensive treatment guidelines. Clin Ther 1996; 18(1): 127–49

    Article  PubMed  Google Scholar 

  2. Hoerger TJ, Downs KE, Lakshmanan MC, et al. Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal health risks. J Womens Health Gend Based Med 1999; 8(8): 1077–89

    Article  PubMed  CAS  Google Scholar 

  3. Tahara Y, Ishii Y. Apatite cement containing cis-diamminedichloroplatinum implanted in rabbit femur for sustained release of the anticancer drug and bone formation. J Orthop Sci 2001; 6(6): 556–65

    Article  PubMed  CAS  Google Scholar 

  4. Kato H, Neo M, Tamura J, et al. Bone bonding in bioactive glass ceramics combined with a new synthesized agent TAK-778. J Biomed Mater Res 2001; 57(2): 291–9

    Article  PubMed  CAS  Google Scholar 

  5. Sánchez E, Baro M, Soriano I, et al. In vivo-in vitro study of biodegradable and osteointegrable gentamicin bone implants. Eur J Pharm Biopharm 2001; 52(2): 151–8

    Article  PubMed  Google Scholar 

  6. Woo BH, Fink BF, Page R, et al. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm Res 2001; 18(12): 1747–53

    Article  PubMed  CAS  Google Scholar 

  7. Talmage RV. Morphological and physiological consideration in a new concept of calcium transport in bone. Am J Anat 1970; 129(4): 467–76

    Article  PubMed  CAS  Google Scholar 

  8. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18(2): 75–85

    Article  PubMed  CAS  Google Scholar 

  9. Cantrill JA, Anderson DC. Treatment of Pagets’s disease of bone. Clin Endocrinol (Oxf) 1990; 32(4): 507–18

    Article  CAS  Google Scholar 

  10. Heath D. The treatment of hypercalcaemia of malignancy. Clin Endocrinol (Oxf) 1991; 34(2): 155–7

    Article  CAS  Google Scholar 

  11. van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; II (8566): 983–5

    Article  Google Scholar 

  12. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322(18): 1265–71

    Article  PubMed  CAS  Google Scholar 

  13. Myers HM. Structure-activity relationships (SAR) of hydroxyapatite-binding molecules. Calcif Tissue Int 1987; 40(6): 344–8

    Article  PubMed  CAS  Google Scholar 

  14. Bisaz S, Jung A, Fleisch H. Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives. Clin Sci Mol Med 1978; 54(3): 265–72

    PubMed  CAS  Google Scholar 

  15. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In: Baker PF, editor. Handbook of experimental pharmacology. Vol. 83. Berlin-Heidelberg: Springer, 1988: 441–66

    Google Scholar 

  16. Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 1995; 3(4): 273–82

    Article  PubMed  CAS  Google Scholar 

  17. Tsushima N, Yabuki M, Harada H, et al. Tissue distribution and pharmacological potential of SM-16896, a novel oestrogenbisphosphonate hybrid compound. J Pharm Pharmacol 2000; 52(1): 27–37

    Article  PubMed  CAS  Google Scholar 

  18. Hirabayashi H, Takahashi T, Fujisaki J, et al. Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS). J Control Release 2001; 70 (1–2): 183–91

    Article  PubMed  CAS  Google Scholar 

  19. Boulenc X, Marti E, Joyeux H, et al. Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochem Pharmacol 1993; 46(9): 1591–600

    Article  PubMed  CAS  Google Scholar 

  20. Lin JH, Chen I-W, de Luna FA, et al. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992; 20(4): 473–8

    PubMed  CAS  Google Scholar 

  21. Lin JH, Duggan DE, Chen I-W, et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991; 19(5): 926–32

    PubMed  CAS  Google Scholar 

  22. Fujisaki J, Tokunaga Y, Takahashi T, et al. Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery. J Pharm Pharmacol 1996; 48(8): 798–800

    Article  PubMed  CAS  Google Scholar 

  23. Fujisaki J, Tokunaga Y, Sawamoto T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J Drug Target 1996; 4(2): 117–23

    Article  PubMed  CAS  Google Scholar 

  24. Smith RL. Excretion of drugs in bile. In: Brodie BB, Gillette JR, editors. Handbook of experimental pharmacology: concepts in biochemical pharmacology. Vol. 28. Berlin: Springer, 1971: 354–89

    Chapter  Google Scholar 

  25. Mönkkönen J, Urtti A, Paronen P, et al. The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro. Drug Metab Dispos 1989; 17(6): 690–3

    PubMed  Google Scholar 

  26. Mönkkönen J, Ylitalo P. The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice: the effects of vehicle and the route of administration. Eur J Drug Metab Pharmacokinet 1990; 15(3): 239–43

    Article  PubMed  Google Scholar 

  27. Mönkkönen J, Rooijen N, Ylitalo P. Effects of clodronate and pamidronate on splenic and hepatic phagocytic cells of mice. Pharmacol Toxicol 1991; 68(4): 284–6

    Article  PubMed  Google Scholar 

  28. Hirabayashi H, Sawamoto T, Fujisaki J, et al. Dose dependent pharmacokinetics and disposition of bisphosphonic prodrug of diclofenac based on Osteotropic Drug Delivery System (ODDS). Biopharm Drug Dispos 2002; 23(8): 307–15

    Article  PubMed  CAS  Google Scholar 

  29. Hirabayashi H, Sawamoto T, Fujisaki J, et al. Relationship between physicochemical and osteotropic properties of bisphosphonic derivatives: rational design for osteotropic drug delivery system (ODDS). Pharm Res 2001; 18(5): 646–51

    Article  PubMed  CAS  Google Scholar 

  30. Fleisch H. Diphosphonates: history and mechanisms of action. Metab Bone Dis Relat Res 1981; 3 (4–5): 279–87

    Article  PubMed  CAS  Google Scholar 

  31. van Beek E, Hoekstra M, van de Ruit M, et al. Structure requirement of bisphosphonate actions in vitro. J Bone Miner Res 1994; 9(12): 1875–82

    Article  PubMed  CAS  Google Scholar 

  32. Sunberg R, Ebetino FH, Mosher CT, et al. Designing drugs for stronger bones. Chemtech 1991; 21: 304–9

    CAS  Google Scholar 

  33. Cohen H, Solomon V, Alferiev IS, et al. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm Res 1998; 15(4): 606–13

    Article  PubMed  CAS  Google Scholar 

  34. Cohen H, Alferiev IS, Mönkkönen J, et al. Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylene-1,1-bisphosphonic acid betaine (ISA-13-1), a novel bisphosphonate. Pharm Res 1999; 16(9): 1399–406

    Article  PubMed  CAS  Google Scholar 

  35. Hoffman A, Stepensky D, Ezra A, et al. Mode of administration-dependent pharmacokinetics of bisphosphonate and bio-availability determination. Int J Pharm 2001; 220 (1–2): 1–11

    Article  PubMed  CAS  Google Scholar 

  36. Gil L, Han Y, Opas EE, et al. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 1999; 7(5): 901–19

    Article  PubMed  CAS  Google Scholar 

  37. Bauss F, Esswein A, Reiff K, et al. Effect of 17β-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17β-estradiol serum kinetics and bone mass in rats. Calcif Tissue Int 1996; 59(3): 168–73

    Article  PubMed  CAS  Google Scholar 

  38. Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. IV: effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats. J Drug Target 1998; 5(2): 129–38

    Article  PubMed  CAS  Google Scholar 

  39. Fujisaki J, Tokunaga Y, Takahashi T, et al. Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. V: biological disposition and targeting characteristics of osteotropic estradiol. Biol Pharm Bull 1997; 20(11): 1183–7

    Article  PubMed  CAS  Google Scholar 

  40. Herczegh P, Buxton TB, McPherson III JC, et al. Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials. J Med Chem 2002; 45(11): 2338–41

    Article  PubMed  CAS  Google Scholar 

  41. Klenner T, Valenzuela-Paz P, Keppler BK, et al. Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo. Cancer Treat Rev 1990; 17 (2–3): 253–9

    Article  PubMed  CAS  Google Scholar 

  42. Klenner T, Wingen F, Keppler BK, et al. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J Cancer Res Clin Oncol 1990; 116(4): 341–50

    Article  PubMed  CAS  Google Scholar 

  43. Klenner T, Wingen F, Keppler B, et al. Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat. Clin Exp Metastasis 1990; 8(4): 345–59

    Article  PubMed  CAS  Google Scholar 

  44. Sturtz G, Couthon H, Fabulet O, et al. Synthesis of gembisphosphonic methotrexate conjugates and their biological response towards Walkers’s osteosarcoma. Eur J Med Chem 1993; 28: 899–903

    Article  CAS  Google Scholar 

  45. Hosain F, Spencer RP, Couthon HM, et al. Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med 1996; 37(1): 105–7

    PubMed  CAS  Google Scholar 

  46. Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001; 45(1): 91–9

    PubMed  CAS  Google Scholar 

  47. Lamb HM, Faulds D. Samarium 153Sm lexidronam. Drugs Aging 1997; 11(5): 413–8

    Article  PubMed  CAS  Google Scholar 

  48. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34(7): 1031–6

    PubMed  CAS  Google Scholar 

  49. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996; 41(10): 2027–42

    Article  PubMed  CAS  Google Scholar 

  50. Mundy GR. Pathogenesis of osteoporosis and challenges for drug delivery. Adv Drug Deliv Rev 2000; 42(3): 165–73

    Article  PubMed  CAS  Google Scholar 

  51. Gambrell Jr RD. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 1982; 37(4): 457–74

    PubMed  Google Scholar 

  52. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332(24): 1589–93

    Article  PubMed  CAS  Google Scholar 

  53. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. J Clin Invest 1979; 64(1): 145–54

    Article  PubMed  CAS  Google Scholar 

  54. Orme MW, Labroo VM. Synthesis of β-estradiol-3-benzoate-17-(succinyl-12A-tetracycline): a potential bone-seeking estrogen. Bioorg Med Chem Lett 1994; 4(11): 1375–80

    Article  CAS  Google Scholar 

  55. Yokogawa K, Miya K, Sekido T, et al. Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 2001; 142(3): 1228–33

    Article  PubMed  CAS  Google Scholar 

  56. Sekido T, Sakura N, Higashi Y, et al. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Target 2001; 9(2): 111–21

    Article  PubMed  CAS  Google Scholar 

  57. Uludag H, Kousinioris N, Gao T, et al. Bisphosphonate conjugation to proteins as a means to impart bone affinity. Biotechnol Prog 2000; 16(2): 258–67

    Article  PubMed  CAS  Google Scholar 

  58. Uludag H, Gao T, Wohl GR, et al. Bone affinity of a bisphosphonate-conjugated protein in vivo. Biotechnol Prog 2000; 16(6): 1115–8

    Article  PubMed  CAS  Google Scholar 

  59. Uludag H, Yang J. Targeting systemically administered proteins to bone by bisphosphonate conjugation. Biotechnol Prog 2002; 18(3): 604–11

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Financial support for this manuscript was provided by Fujisawa Pharmaceutical Co. Ltd. The authors wish to thank Bindu Gadani, M.S., for critical reading and reviewing of the manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Company, Kashima 2-chome, Yodogawa-ku, Osaka, 1-6, 532-8514, Japan

    Hideki Hirabayashi

  2. Manufacturing Technology, Fujisawa Pharmaceutical Company, Osaka, Japan

    Jiro Fujisaki

Authors
  1. Hideki Hirabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiro Fujisaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Hirabayashi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirabayashi, H., Fujisaki, J. Bone-Specific Drug Delivery Systems. Clin Pharmacokinet 42, 1319–1330 (2003). https://doi.org/10.2165/00003088-200342150-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200342150-00002

Keywords

Search

Navigation